Latest Posters

This poster highlights key lipid components, formulation variables and targeting strategies that define modern LNP development, offering insight into how these elements influence therapeutic outcomes.

This poster explores how a robust CRISPR-based screening platform enables the identification of novel regulators of the Treg phenotype to support drug discovery.

This poster presents a high-throughput SPR (HT-SPR) workflow for evaluating FcγR binding, enabling sensitive, simultaneous analysis of receptor variants with faster assays and reduced reagent use.

This poster explores how small molecule microarrays (SMM) simplifies the drug discovery workflow, from microarray printing to target screening, delivering fast, reliable results.

This poster explores an innovative technology that simplifies the construction of bispecific antibodies, enabling rapid and efficient assembly of bispecific constructs while maintaining high purity and yield.

This poster outlines a scalable workflow combining tangential flow filtration and size exclusion chromatography to effectively isolate and purify exosomes, removing contaminants including media, serum and host cell proteins, DNA and serum components.

This poster describes the use of CRISPR-ready iPSCs, which are engineered to constitutively express Cas9, enabling the rapid generation of high-efficiency gene knockouts and CRISPR screens in a functional, physiologically relevant cell background.

With this poster, dive into the world of mass spectrometry troubleshooting, and discover detailed tables listing the accurate mass of elements, organic solvents and potential contaminant ions.

Biolayer Interferometry (BLI) technology has greatly advanced the process of antibody discovery, and the latest platforms offer reliable, high precision analysis which researchers can rely on.

Designing and performing assays that accurately measure small molecule binding kinetics is an important part of the drug discovery process. It allows researchers to predict the efficacy of potential novel therapeutics and make quick decisions about weak binders.